CureVac appoints a new CureVac: The biotech company from Tübingen, best known for its COVID-19 vaccine candidate, announced on Friday that Antony Blanc was appointed Chief Business Officer and Chief Commercial Officer. “In this role, he is responsible for expanding the existing network of partnerships that will help CureVac grow,” said CureVac. In addition, Blanc should set up a sales organization and increase the competitiveness and value of the company’s development programs.
Blanc previously worked for GSK Vaccines and as an Associate Partner at McKinsey & Company for European biotech clients.
“Antony comes to CureVac at exactly the right time,” said Franz-Werner Haas, CEO of CureVac, on Friday about the personnel. “With him we have gained another very experienced team member on the board who will support us significantly in the further business development and growth of our company,” said the manager.
Live stream today from 6 p.m .:
European champion in e-mobility – how the automotive industry combines climate policy and structural change